Page 41 - Binder2
P. 41
Figure 3. “Biologic Therapy: Revenue vs. Efficacy Over Time.”
Illustrative chart based on trends from IQVIA (2023), Vermeire et al.
(2018), and Hanauer et al. (2010), highlighting the front-loaded
revenue model and declining clinical efficacy due to
immunogenicity.
This chart illustrates the divergence between financial
return and therapeutic durability in biologic drug treatment.
While revenue per patient is often front-loaded—captured
largely in the first 12 to 18 months—clinical efficacy tends
to decline over time due to the development of anti-drug
antibodies (ADAs), a phenomenon known as tolerization.
As efficacy wanes, patients frequently require dose
escalation, combination therapy, or drug switching, further
increasing system costs while delivering diminishing
39
